ProMIS Neurosciences
PMNProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapies for neurodegenerative diseases and other misfolded protein disorders.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapies for neurodegenerative diseases and other misfolded protein disorders. The company utilizes a proprietary computational discovery platform to identify disease-specific epitopes, enabling the creation of antibodies that selectively target toxic misfolded proteins while sparing healthy, functional proteins.
ProMIS differentiates itself through an in silico rational selection approach that targets conformational epitopes, aiming for higher selectivity and safety than traditional immunization methods.
Questions, answered.
- What is ProMIS Neurosciences's market cap?
- ProMIS Neurosciences (PMN) has a market capitalization of $105.1M and trades on NASDAQ.
- Who are ProMIS Neurosciences's competitors?
- ProMIS Neurosciences's key competitors include Biogen Inc., Eli Lilly and Company, Prothena Corporation plc Ordinary Shares, and others. These companies compete in similar markets and product categories.
- Who does ProMIS Neurosciences partner with?
- ProMIS Neurosciences's notable partners include University of British Columbia.
- Where is ProMIS Neurosciences headquartered?
- ProMIS Neurosciences is headquartered in Canada and employs approximately 7 people. It has been publicly traded since 2005.